| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 06/28/2001 | WO2001046204A1 Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors |
| 06/28/2001 | WO2001046203A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | WO2001046196A1 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| 06/28/2001 | WO2001046191A1 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives |
| 06/28/2001 | WO2001046184A1 3-thiazol-4-yl-pyprolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | WO2001046176A2 Non peptide tachykinin receptor antagonists |
| 06/28/2001 | WO2001046172A1 Pyrazole cyclic amp-specific pde inhibitors |
| 06/28/2001 | WO2001046171A1 Amidine derivatives which are inhibitors of nitric oxide synthase |
| 06/28/2001 | WO2001046170A1 Amidine derivatives which are inhibitors of nitric oxide synthase |
| 06/28/2001 | WO2001046166A2 Partially saturated calcium channel blockers |
| 06/28/2001 | WO2001046155A1 Potassium channel inhibitors |
| 06/28/2001 | WO2001046151A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 06/28/2001 | WO2001046136A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | WO2001045751A1 Angiogenesis and vascular permeability modulators and inhibitors |
| 06/28/2001 | WO2001045741A2 Methods for preparing pharmaceutical formulations |
| 06/28/2001 | WO2001045739A1 Remedies and/or preventives for nervous system disorders |
| 06/28/2001 | WO2001045730A2 Tweak receptor |
| 06/28/2001 | WO2001045725A2 Treatment for inflammatory bowel disease (ibd) and related conditions |
| 06/28/2001 | WO2001045717A2 Pharmaceutical composition comprising a vanadium compound and at least a component selected from a na+/h+ exchanger, cyclo-oxygenase inhibitors and caspase inhibitors |
| 06/28/2001 | WO2001045716A1 Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and a na+/h+ exchange inhibitor |
| 06/28/2001 | WO2001045711A1 Urotensin-ii receptor antagonists |
| 06/28/2001 | WO2001045709A1 Substituted piperazine and piperidine calcium channel blockers |
| 06/28/2001 | WO2001045703A1 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 06/28/2001 | WO2001045700A1 Urotensin-ii receptor antagonists |
| 06/28/2001 | WO2001045694A1 Urotensin-ii receptor antagonists |
| 06/28/2001 | WO2001045663A2 USE OF AROMATIC POLYCYCLIC COMPOUNDS AS ACTIVATORS OF PPARs-TYPE RECEPTORS IN A COSMETIC OR PHARMACEUTICAL COMPOSITION |
| 06/28/2001 | WO2001045641A2 Inhibitors of thrombin induced platelet aggregation |
| 06/28/2001 | WO2001014402A8 Antisense modulation of focal adhesion kinase expression |
| 06/28/2001 | WO2001005974A9 The il-1l1 gene and polypeptide products |
| 06/28/2001 | WO2001002561A3 Mammalian calcium channels and related probes, cell lines and methods |
| 06/28/2001 | WO2000078776A3 Thiophene a2a receptor agonists |
| 06/28/2001 | WO2000078765A3 CHROMENO[4,3,2-de]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS |
| 06/28/2001 | WO2000075144A3 Peroxynitrite decomposition catalysts and methods of use thereof |
| 06/28/2001 | WO2000074710A3 Methods for treating diabetes |
| 06/28/2001 | WO2000071741A3 Dna encoding a human subunit of the 5-ht3 serotonin receptor |
| 06/28/2001 | WO2000070047A3 Full-length molecules expressed in human tissues |
| 06/28/2001 | WO2000068247A3 Serine proteases |
| 06/28/2001 | WO2000066731A3 Recombinant laminin 5 |
| 06/28/2001 | WO2000066104A3 Ace-2 inhibiting compounds and methods of use thereof |
| 06/28/2001 | WO2000063236A3 Adhesion modulatory peptides and methods for use |
| 06/28/2001 | WO2000061180A3 Products and methods for treating ptp lar related diseases |
| 06/28/2001 | WO2000055321A3 Vertebrate protein slit, dna sequence encoding it and uses thereof |
| 06/28/2001 | WO2000040569A8 2-amino-benzoxazinone derivatives for the treatment of obesity |
| 06/28/2001 | WO2000003981A8 Preparation of (s)-2-amino-6,6-dimethoxyhexanoic acid methyl ester via novel dioxolanes |
| 06/28/2001 | US20010005756 New 4-halogenated steroids, their preparation process and intermediates, their use as medicaments and the pharmaceutical compositions containing them |
| 06/28/2001 | US20010005720 Method of treating chronic progressive vascular scarring diseases |
| 06/28/2001 | US20010005719 Compositions and methods for treatment of mitochondrial diseases |
| 06/28/2001 | US20010005714 Amphipathic molecules as cholesterol and other lipid uptake inhibitors |
| 06/28/2001 | DE19962936A1 New beta-aminoacid amide derivatives, are integrin antagonists useful for treating inflammatory, autoimmune or immunological disorders e.g. asthma, diabetes or rheumatoid arthritis |
| 06/28/2001 | DE19962926A1 Comminution of a substance, especially a cardiovascular drug, comprises mixing the substance with lactose and comminuting the mixture in a jet mill |
| 06/28/2001 | DE19960640A1 Neue Stromelysin Inhibitoren New stromelysin inhibitors |
| 06/28/2001 | DE19960204A1 Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament Norlbornylamino substituted derivatives, processes for their preparation, their use as a medicament or diagnostic, and they drug-containing |
| 06/28/2001 | DE19959049A1 Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen Combination of compounds, which inhibit the biological effects of TNF-alpha and CD95L |
| 06/28/2001 | CA2399584A1 Non peptide tachykinin receptor antagonists |
| 06/28/2001 | CA2395714A1 Novel tachykinin-like polypeptides and use thereof |
| 06/28/2001 | CA2395520A1 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| 06/28/2001 | CA2395471A1 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives |
| 06/28/2001 | CA2395202A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | CA2395136A1 Angiogenesis and vascular permeability modulators and inhibitors |
| 06/28/2001 | CA2395113A1 Pyrazole cyclic amp-specific pde inhibitors |
| 06/28/2001 | CA2395102A1 Human kinases |
| 06/28/2001 | CA2395007A1 Transporters and ion channels |
| 06/28/2001 | CA2394864A1 Novel compounds |
| 06/28/2001 | CA2394834A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | CA2394789A1 Proteases |
| 06/28/2001 | CA2394633A1 Therapeutic and/or prophylactic agent for nervous system disorder |
| 06/28/2001 | CA2394603A1 Urotensin-ii receptor antagonists |
| 06/28/2001 | CA2394330A1 Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and at least a component selected from a na+/h+ exchanger inhibitors, cyclo-oxygenase inhibitors and caspase inhibitors |
| 06/28/2001 | CA2394049A1 Vesicle trafficking proteins |
| 06/28/2001 | CA2394015A1 Tweak receptor |
| 06/28/2001 | CA2393855A1 Homologues of human heparanase and splice variants thereof |
| 06/28/2001 | CA2393756A1 Potassium channel inhibitors |
| 06/28/2001 | CA2393724A1 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 06/28/2001 | CA2393646A1 Survivin promotion of angiogenesis |
| 06/28/2001 | CA2393367A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | CA2393363A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | CA2393359A1 Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors |
| 06/28/2001 | CA2392787A1 Nk cell receptor polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | CA2392554A1 Inhibitors of thrombin induced platelet aggregation |
| 06/28/2001 | CA2389479A1 Butyne diol derivatives |
| 06/28/2001 | CA2363837A1 Use of aromatic polycyclic compounds as activators of ppars-type receptors in a cosmetic or pharmaceutical composition |
| 06/27/2001 | EP1110957A1 Benzazole derivatives and their use as JNK modulators |
| 06/27/2001 | EP1110952A1 Carboxylic acid derivates, their preparation and use |
| 06/27/2001 | EP1109925A1 Recombinant adenovirus for tissue specific expression in heart |
| 06/27/2001 | EP1109918A2 Polypeptides, polynucleotides and uses thereof |
| 06/27/2001 | EP1109903A2 Human rna-associated proteins |
| 06/27/2001 | EP1109896A1 Adenovirus formulations for gene therapy |
| 06/27/2001 | EP1109829A1 Human latent transforming growth factor beta binding protein 3 |
| 06/27/2001 | EP1109822A1 Factor 8 homologue nucleic acids, polypeptides, methods, uses |
| 06/27/2001 | EP1109821A1 49 human secreted proteins |
| 06/27/2001 | EP1109814A1 5-heterocyclyl pyrazolo 4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction |
| 06/27/2001 | EP1109813A1 Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists |
| 06/27/2001 | EP1109810A1 Benzonaphthyridine-n-oxides comprising a pde3 and pde4 inhibiting activity |
| 06/27/2001 | EP1109809A1 Pyrroloquinolines for treatment of obesity |
| 06/27/2001 | EP1109804A1 Chemokine receptor antagonists and methods of use therefor |
| 06/27/2001 | EP1109803A1 Substituted imidazoles having cytokine inhibitory activity |
| 06/27/2001 | EP1109801A1 Substituted dihydrobenzopyrans useful as antiarrhythmic agents |
| 06/27/2001 | EP1109799A1 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors |
| 06/27/2001 | EP1109787A1 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
| 06/27/2001 | EP1109786A1 Piperidine derivatives |